Have a feature idea you'd love to see implemented?
Let us know!
DNLI Denali Therapeutics Inc
Price (delayed)
$26.44
Market cap
$3.79B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.86
Enterprise value
$3.76B
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing
Highlights
Denali Therapeutics's debt has decreased by 12% YoY and by 3.5% from the previous quarter
The quick ratio has declined by 30% year-on-year but it has grown by 6% since the previous quarter
Denali Therapeutics's equity has increased by 17% YoY but it has decreased by 4.7% QoQ
The EPS has plunged by 172% YoY
Denali Therapeutics's gross profit has shrunk by 100% YoY and by 100% QoQ
Key stats
What are the main financial stats of DNLI
Market
Valuations
Earnings
Shares outstanding
143.17M
Market cap
$3.79B
Enterprise value
$3.76B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.72
Price to sales (P/S)
3,523.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,967.14
Revenue
$1.27M
EBIT
-$419.62M
EBITDA
-$411.13M
Free cash flow
-$402.1M
Per share
Balance sheet
Liquidity
EPS
-$2.86
Free cash flow per share
-$2.38
Book value per share
$9.73
Revenue per share
$0.01
TBVPS
$8.9
Total assets
$1.5B
Total liabilities
$115.51M
Debt
$48.75M
Equity
$1.39B
Working capital
$853.85M
Debt to equity
0.04
Current ratio
12.46
Quick ratio
12.02
Net debt/EBITDA
0.06
Margins
Efficiency
Dividend
EBITDA margin
-32,448.8%
Gross margin
100%
Net margin
-33,121.9%
Operating margin
-37,938%
Return on assets
-30.7%
Return on equity
-33.6%
Return on invested capital
-33.8%
Return on capital employed
-29.4%
Return on sales
-33,119.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DNLI stock price
How has the Denali Therapeutics stock price performed over time
Intraday
1.38%
1 week
-3.57%
1 month
-12.8%
1 year
34.21%
YTD
23.21%
QTD
-9.23%
Financial performance
How have Denali Therapeutics's revenue and profit performed over time
Revenue
$1.27M
Gross profit
$1.27M
Operating income
-$480.68M
Net income
-$419.65M
Gross margin
100%
Net margin
-33,121.9%
DNLI's operating income has dropped by 195% year-on-year and by 148% since the previous quarter
Denali Therapeutics's gross profit has shrunk by 100% YoY and by 100% QoQ
DNLI's revenue has dropped by 100% year-on-year and by 100% since the previous quarter
Growth
What is Denali Therapeutics's growth rate over time
Valuation
What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
2.72
P/S
3,523.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,967.14
The EPS has plunged by 172% YoY
DNLI's price to book (P/B) is 40% less than its 5-year quarterly average of 4.5 but 13% more than its last 4 quarters average of 2.4
Denali Therapeutics's equity has increased by 17% YoY but it has decreased by 4.7% QoQ
DNLI's revenue has dropped by 100% year-on-year and by 100% since the previous quarter
Efficiency
How efficient is Denali Therapeutics business performance
The return on assets has dropped by 195% since the previous quarter
The return on equity has dropped by 192% since the previous quarter and by 163% year-on-year
The return on invested capital has dropped by 191% since the previous quarter and by 158% year-on-year
Dividends
What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DNLI.
Financial health
How did Denali Therapeutics financials performed over time
The quick ratio has declined by 30% year-on-year but it has grown by 6% since the previous quarter
The current ratio has contracted by 29% YoY but it has grown by 6% from the previous quarter
Denali Therapeutics's debt is 96% less than its equity
DNLI's debt to equity is up by 33% since the previous quarter but it is down by 20% year-on-year
Denali Therapeutics's equity has increased by 17% YoY but it has decreased by 4.7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.